CN114026088A - Jak2抑制剂的结晶形式 - Google Patents

Jak2抑制剂的结晶形式 Download PDF

Info

Publication number
CN114026088A
CN114026088A CN202080027762.4A CN202080027762A CN114026088A CN 114026088 A CN114026088 A CN 114026088A CN 202080027762 A CN202080027762 A CN 202080027762A CN 114026088 A CN114026088 A CN 114026088A
Authority
CN
China
Prior art keywords
crystalline
crystalline form
compound
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080027762.4A
Other languages
English (en)
Chinese (zh)
Inventor
B·罗伯特
P·比洛特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Biomedicines Inc
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of CN114026088A publication Critical patent/CN114026088A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080027762.4A 2019-02-12 2020-02-11 Jak2抑制剂的结晶形式 Pending CN114026088A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FRFR1902018 2019-02-12
FR1902018A FR3092581A1 (fr) 2019-02-12 2019-02-12 Formes cristallines d'un inhibiteur de jak2
PCT/US2020/017764 WO2020167844A1 (en) 2019-02-12 2020-02-11 Crystalline forms of a jak2 inhibitor

Publications (1)

Publication Number Publication Date
CN114026088A true CN114026088A (zh) 2022-02-08

Family

ID=68281482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080027762.4A Pending CN114026088A (zh) 2019-02-12 2020-02-11 Jak2抑制剂的结晶形式

Country Status (13)

Country Link
US (1) US20220332706A1 (https=)
EP (1) EP3927704A4 (https=)
JP (2) JP2022520083A (https=)
KR (1) KR20210148110A (https=)
CN (1) CN114026088A (https=)
AU (1) AU2020221796A1 (https=)
BR (1) BR112021015318A2 (https=)
EA (1) EA202192237A1 (https=)
FR (1) FR3092581A1 (https=)
IL (1) IL285427A (https=)
MX (1) MX2021009423A (https=)
SG (1) SG11202108607QA (https=)
WO (1) WO2020167844A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
US12559463B2 (en) * 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013013195A1 (en) * 2011-07-21 2013-01-24 Sanofi Compositions and methods for treating polycythemia vera and essential thrombocythemia
CN103282036A (zh) * 2010-11-07 2013-09-04 塔格根公司 用于治疗骨髓纤维化的组合物和方法
CN103626742A (zh) * 2005-11-01 2014-03-12 塔格根公司 激酶的联-芳基间-嘧啶抑制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10040804B2 (en) * 2016-12-21 2018-08-07 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626742A (zh) * 2005-11-01 2014-03-12 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
CN103282036A (zh) * 2010-11-07 2013-09-04 塔格根公司 用于治疗骨髓纤维化的组合物和方法
WO2013013195A1 (en) * 2011-07-21 2013-01-24 Sanofi Compositions and methods for treating polycythemia vera and essential thrombocythemia

Also Published As

Publication number Publication date
SG11202108607QA (en) 2021-09-29
JP2022520083A (ja) 2022-03-28
BR112021015318A2 (pt) 2021-10-05
WO2020167844A1 (en) 2020-08-20
JP2025032217A (ja) 2025-03-11
FR3092581A1 (fr) 2020-08-14
MX2021009423A (es) 2021-11-17
AU2020221796A1 (en) 2021-08-12
IL285427A (en) 2021-09-30
KR20210148110A (ko) 2021-12-07
EP3927704A4 (en) 2022-12-28
US20220332706A1 (en) 2022-10-20
EP3927704A1 (en) 2021-12-29
EA202192237A1 (ru) 2021-12-14

Similar Documents

Publication Publication Date Title
CN102985423B (zh) 嘌呤衍生物的结晶形式
JP5289948B2 (ja) ４−メチル−ｎ−［３−（４−メチル−イミダゾール−１−イル）−５−トリフルオロメチル−フェニル］−３−（４−ピリジン−３−イル−ピリミジン−２−イルアミノ）−ベンズアミドの結晶形態
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
CN113840604B (zh) Jak2抑制剂的结晶形式
JP2025032217A (ja) Ｊａｋ２阻害剤の結晶形態
EP3551617A1 (en) Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
US20160354351A1 (en) Solid state forms of vemurafenib hydrochloride
JP2025505655A (ja) １－（（ｓ）－４－（（ｒ）－７－（６－アミノ－４－メチル－３－（トリフルオロメチル）ピリジン－２－イル）－６－クロロ－８－フルオロ－２－（（（ｓ）－１－メチルピロリジン－２－イル）メトキシ）キナゾリン－４－イル）－３－メチルピペラジン－１－イル）プロパ－２－エン－１－オンの固体形態
EP3430004B1 (en) Solid state forms of nilotinib salts
JP2023536892A (ja) Ｊａｋ阻害剤化合物及びその使用
US20200216427A1 (en) Solid state forms of entrectinib
KR20180086508A (ko) 치환된 5,6-디하이드로-6-페닐벤조[f]이소퀴놀린-2-아민 화합물의 고체 형태
JP2025503010A (ja) キナーゼ阻害剤の塩結晶形及び遊離塩基結晶形
EP3441387A1 (en) Pi3k inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof
JP2023531078A (ja) 化合物の結晶形態
TWI680977B (zh) ｃ-Ｍｅｔ抑制劑之多晶形式及共晶
TW202506661A (zh) 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法
TW202442647A (zh) 一種含氮四環化合物的結晶形式及其製備方法
HK40106793A (zh) Bcl-2抑制剂的固体形式、其制备方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination